Section Arrow
VRTX.NASDAQ
- Vertex Pharmaceuticals
Quotes are at least 15-min delayed:2025/12/21 08:09 EST
Regular Hours
Last
 456.2
+8.82 (+1.97%)
Day High 
460.4 
Prev. Close
447.38 
1-M High
463.85 
Volume 
5.56M 
Bid
454.01
Ask
456.3
Day Low
445.51 
Open
446.86 
1-M Low
418.53 
Market Cap 
113.51B 
Currency 美元 
P/E 31.48 
%Yield -- 
10-SMA 448.47 
20-SMA 441.63 
50-SMA 429.33 
52-W High 519.68 
52-W Low 362.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
14.21/19.82
Enterprise Value
115.17B
Balance Sheet
Book Value Per Share
68.26
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
11.02B
Operating Revenue Per Share
38.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
FOLDAmicus Therapeutics14.18+3.29+30.21%-- 
RXRXRecursion Pharmaceuticals4.26-0.18-4.05%-- 
IBRXImmunityBio2.08-0.01-0.48%-- 
PBMPsyence Biomedical Ltd1-0.46-31.51%0.04PE
GOVXGeoVax Labs0.1592-0.0809-33.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.